Anti‐Porphyromonas gingivalis Antibody Levels in Patients With Stroke and Atrial Fibrillation: A Systematic Review and Meta‐Analysis

Abstract

ObjectivesAtrial fibrillation (AF) and stroke are two highly related conditions, with periodontitis and periodontal pathogens, such as Porphyromonas gingivalis (Pg), appearing to be the most prominent common risk factors. In this study, we evaluated studies assessing Pg infection via serum/plasma anti‐Pg antibodies in patients with AF and/or stroke.Material and MethodsOnline databases (PubMed, Scopus, Embase, and the Web of Science) were screened for studies showing the association between anti‐Pg antibodies with stroke and/or AF. Relevant data were extracted, and a subsequent random‐effects meta‐analysis was performed to calculate the pooled odds ratio (OR) or standardized mean difference (SMD) and 95% confidence intervals (CIs) for Pg seropositivity or anti‐Pg antibody levels in stroke patients compared to controls.ResultsSixteen studies were included in the systematic review. Based on the meta‐analysis performed, there was no significant difference in Pg IgA and IgG levels between patients with stroke and controls (IgA: SMD 0.11, 95% CI −0.02 to 0.25, p = 0.1; IgG: SMD −0.12, 95% CI −1.24 to 0.99, p = 0.83). Similarly, no difference was observed between these groups in terms of Pg IgA and IgG seropositivity (IgA: OR 1.63, 95% CI 1.06–2.50, p = 0.026; IgG: OR 2.30, 95% CI 1.39–3.78, p < 0.001). Subsequently, we reviewed the results of six articles investigating serum or plasma IgG antibodies against Pg in patients with AF. Our results revealed a strict association between Pg infection and AF, with AF patients exhibiting either higher anti‐Pg antibody levels or a higher prevalence of positive serum Pg antibodies.ConclusionsOur study supports the clinical utility of Pg infection assessment in patients with periodontitis and those with AF and solicits more focused studies to corroborate its use in clinical settings to enhance overall outcomes, reduce the risk of complications like stroke, and help fine‐tune personalized therapies.